Clinical Trials Sponsored by Takeda Canada, Inc.

Total 643 results

Millennium Pharmaceuticals, Inc.

Completed

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

Digestive System Disease

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

Advanced Solid Neoplasm

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Multiple Myeloma | Relapsed/Refractory

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Diabetic Gastroparesis | Idiopathic Gastroparesis

United States, Belgium, Japan, Poland
Millennium Pharmaceuticals, Inc.

Approved for marketing

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Carcinoma, Non-Small-Cell Lung
Millennium Pharmaceuticals, Inc.

Completed

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

United States, Israel, Spain, France, Ireland, Canada, Germany, Czechia, Italy, Netherlands, Belgium, Bulgaria
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Shire
Quintiles, Inc.

Completed

Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease

Gaucher Disease

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors

Neoplasms, Advanced Solid

Netherlands
Millennium Pharmaceuticals, Inc.

Completed

Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

Lymphoma | Advanced Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Melanoma | Solid Tumor | Metastatic Melanoma | Neoplasm

United States, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Obstructive Sleep Apnea

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Light-Chain Amyloidosis

United States, Canada, France, Germany, Italy
Takeda
Zinfandel Pharmaceuticals Inc.

Terminated

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Germany, Switzerland, United Kingdom, Australia
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Small Cell Lung Cancer | Ovarian Cancer | Advanced Solid Tumors

Japan, Korea, Republic of
Millennium Pharmaceuticals, Inc.

Completed

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Multiple Myeloma | Advanced Solid Tumors

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Lymphoma | Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors | Lymphomas

Singapore
Millennium Pharmaceuticals, Inc.

Terminated

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Advanced Malignant Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants

Healthy Participants

United States
Millennium Pharmaceuticals, Inc.

Completed

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Fallopian Tube Cancer | Breast Carcinoma | Ovarian Carcinoma | Peritoneal Cancer

United States
Millennium Pharmaceuticals, Inc.

Completed

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Lymphoma | Nonhematologic Malignancies

United States
Millennium Pharmaceuticals, Inc.

Terminated

MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Recurrent Gastric Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Advanced Gastrointestinal Carcinoma | Recurrent Gastrointestinal Carcinoma

Taiwan, Korea, Republic of, Japan
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

United States
SBI ALApharma Canada, Inc.

Recruiting

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

Breast Cancer | Breast Neoplasm Female

United States
Aquinox Pharmaceuticals (Canada) Inc.

Completed

Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study (DDI-COC)

Healthy Volunteer

Netherlands
Aquinox Pharmaceuticals (Canada) Inc.

Completed

Efficacy and Safety of AQX-1125 in Unstable COPD (FLAGSHIP)

COPD

United States, New Zealand, Poland, Australia, Denmark, Finland, Hungary, Sweden
Janssen-Ortho Inc., Canada

Terminated

A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication

Schizophrenia

Canada, United Kingdom, Australia, Ireland
Janssen-Ortho Inc., Canada

Completed

Impact of Tolerability Issues on Chronic Pain

Pain
Janssen-Ortho Inc., Canada

Completed

A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers

Pharmacokinetics
Janssen-Ortho Inc., Canada

Completed

A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

Multiple Myeloma
Janssen-Ortho Inc., Canada

Completed

An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method

Female Contraception
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Canada Pharmaceutical Inc.; Lundbeck Canada Inc.

Completed

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Major Depressive Disorder

Canada
Aquinox Pharmaceuticals (Canada) Inc.

Unknown

Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome (LEADERSHIP 301)

Interstitial Cystitis | Painful Bladder Syndrome | Bladder Pain Syndrome | Chronic Interstitial Cystitis

United States, Belgium, Canada, Czechia, Denmark, Hungary, Latvia, Netherlands, Poland, Romania, Spain, United Kingdom
Aquinox Pharmaceuticals (Canada) Inc.

Completed

Efficacy and Safety of AQX-1125 in IC/BPS (LEADERSHIP)

Interstitial Cystitis | Bladder Pain Syndrome

United States, Canada
Janssen-Ortho Inc., Canada

Terminated

An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function

Multiple Myeloma

Canada
Janssen-Ortho Inc., Canada

Completed

A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole

GERD
Janssen-Ortho Inc., Canada

Completed

Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.

Gastroesophageal Reflux | Heartburn
Janssen-Ortho Inc., Canada

Completed

A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

Anemia | Kidney Failure | Left Ventricular Hypertrophy
Janssen-Ortho Inc., Canada

Completed

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)

Autistic Disorder | Developmental Disabilities | Rett Syndrome | Asperger Syndrome | DCild Development Disorders, Pervasive
Janssen-Ortho Inc., Canada

Completed

An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone

Schizophrenia
Millennium Pharmaceuticals, Inc.
Seagen Inc.

Completed

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (ALCANZA)

Mycosis Fungoides | Cutaneous T-Cell Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma

United States, France, Italy, United Kingdom, Spain, Switzerland, Brazil, Austria, Belgium, Germany, Poland, Australia
Otsuka Canada Pharmaceutical Inc.

Recruiting

Canadian Medical Assessment of JINARC™ Outcomes Registry (C-MAJOR)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Canada
Aquinox Pharmaceuticals (Canada) Inc.

Terminated

Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Canada, United States
Janssen-Ortho Inc., Canada

Withdrawn

A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.

Anemia | Blood Transfusion | Orthopedic Surgery
Janssen-Ortho Inc., Canada

Completed

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Prostate Neoplasms

Canada

3

Subscribe